Appendix E - National Coverage Determinations Manual / Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions

Why This Topic Matters

Understanding this coverage policy helps users evaluate whether ESA-related services fall within nationally covered circumstances under Medicare and where non-covered situations or contractor discretion may apply.

Article Sections

1. A. General

   Provides background on ESAs and the general purpose of the policy. It also notes the article’s clinical and regulatory context.

2. B. Nationally Covered Indications

   Summarizes the covered oncology-related scenarios and the broad treatment conditions tied to Medicare coverage. This section focuses on the scope of nationally covered use and related clinical considerations.

3. C. Nationally Non-Covered Indications

   Lists categories of ESA use that are not nationally covered under the policy. It distinguishes situations excluded because of underlying disease factors or other clinical circumstances.

4. D. Other

   Explains that local Medicare contractors may address uses not specifically covered in the national determination. It also points readers to related Medicare manual guidance.